Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToleroMune Ragweed in Ragweed Allergic Subjects
NCT01198613Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Sep 2010
- Primary completion
- Aug 2011
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ragweed-spire in allergic rhinoconjunctivitis (ARC), sponsored by NIOX Group. Started Sep 2010; status: completed.
02
Drugs
ragweed-spire
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01198613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01198613.